2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

leukemic cells

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

4

Peptides

2

Inhibitory Antibodies

9

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100490B
    Rilmenidine phosphate

    		Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy Cardiovascular Disease Cancer
    Rilmenidine phosphate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine phosphate is an alpha 2-adrenoceptor agonist. Rilmenidine phosphate induces autophagy. Rilmenidine phosphate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na +/H + antiport. Rilmenidine phosphate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .
    Rilmenidine phosphate
  • HY-100490A
    Rilmenidine hemifumarate

    		Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy Cardiovascular Disease Cancer
    Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine hemifumarate is an alpha 2-adrenoceptor agonist. Rilmenidine hemifumarate induces autophagy. Rilmenidine hemifumarate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na +/H + antiport. Rilmenidine hemifumarate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .
    Rilmenidine hemifumarate
  • HY-128067
    5-(N,N-Hexamethylene)-amiloride
    1 Publications Verification

    Hexamethylene amiloride; HMA

    		 Sodium Channel HIV Apoptosis Infection Cancer
    5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na +/H + exchanger inhibitor, which decreases the intracellular pH (pHi) and induces apoptosis in leukemic cells. 5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) is also an inhibitor of the HIV-1 Vpu virus ion channel and inhibits mouse hepatitis virus (MHV) replication and human coronavirus 229E (HCoV229E) replication in cultured L929 cells with EC50s of 3.91 μM and 1.34 μM, respectively .
    5-(N,N-Hexamethylene)-amiloride
  • HY-100490
    Rilmenidine

    		Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy Cardiovascular Disease Cancer
    Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an alpha 2-adrenoceptor agonist. Rilmenidine induces autophagy. Rilmenidine acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na +/H + antiport. Rilmenidine modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .
    Rilmenidine
  • HY-150566
    BCR-ABL-IN-5

    		Bcr-Abl Cancer
    BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-Abl WT and Bcr-Abl T3151 with the IC50 value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells .
    BCR-ABL-IN-5
  • HY-128888B
    (S,R)-GSK321

    		Isocitrate Dehydrogenase (IDH) Cancer
    (S,R)-GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. (S,R)-GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. (S,R)-GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .
    (S,R)-GSK321
  • HY-111617
    BTR-1

    		Apoptosis Cancer
    BTR-1 is an active anti-cancer agent, causes S phase arrest, and affects DNA replication in leukemic cells. BTR-1 activates apoptosis and induces cell death .
    BTR-1
  • HY-N3514
    Kuwanon E

    		Others Cancer
    Kuwanon E is a flavonoid isolated from Morus alba, cytotoxic to human monocytic leukemic cell lines, and reduces the level of IL-1β .
    Kuwanon E
  • HY-N10071
    Poricoic acid G

    		Others Cancer
    Poricoic acid G is a triterpenoid that can be isolated from Poria cocos. Poricoic acid G has a significant cytotoxic effect on leukemia cells and is a potential potent anti-leukemic compound in humans .
    Poricoic acid G
  • HY-117220
    Aspochalasin M

    		Others Cancer
    Aspochalasin M is a colorless solid. Aspochalasin M shows modest activity against HL-60 cells with an IC50 of 20.0 μM. Aspochalasin M has the potential for the research of leukemic disease .
    Aspochalasin M
  • HY-100423
    Eltanexor
    1 Publications Verification

    KPT-8602
    Eltanexor (KPT-8602) is a second-generation, highly specific and orally active exportin-1 (XPO1) inhibitor with potent anti-leukemic activity. Eltanexor (KPT-8602) inhibits XPO1-dependent nuclear export (EC50=60.9 nM) by directly targeting XPO1. Eltanexor (KPT-8602) induces Caspase-dependent apoptosis in a panel of leukemic cell lines .
    Eltanexor
  • HY-N9359
    Toddaculin

    		Apoptosis
    Toddaculin is a natural coumarin that can induce differentiation and apoptosis in leukemic cells. Toddaculin suppresses excess osteoclast activity and enhances osteoblast differentiation and mineralization. Toddaculin also exhibits anti-inflammatory activity .
    Toddaculin
  • HY-W588250
    Surfactin C1

    		Integrin Inflammation/Immunology
    Surfactin C1 is an amphiphilic biosurfactants. Surfactin C1 inhibits leukemic cell (HL-60) adhesion to human umbilical vein endothelial cells (HUVEC). Surfactin C1 inhibits adhesion melecules expression, such as ICAM-1 and VCAM-1 .
    Surfactin C1
  • HY-149334
    ZLD115

    		Fat Mass and Obesity-associated Protein (FTO) Metabolic Disease
    ZLD115 (compound 44) is a FB23-derivated inhibitor of Fat Mass and Obesity-associated Protein (FTO). ZLD115 is an antileukemic agent, exhibiting antiproliferative activity against leukemic cell lines .
    ZLD115
  • HY-N10789
    (2S)-4'-Hydroxy-7-methoxyflavan

    		Others Cancer
    (2S)-4'-Hydroxy-7-methoxyflavan is a Flavan. Flavan (4′-hydroxy-7-methoxyflavan) showed an important cytotoxic effect on human leukemic Molt 4 cells .
    (2S)-4'-Hydroxy-7-methoxyflavan
  • HY-123954
    Casein Kinase inhibitor A51

    		Casein Kinase CDK Apoptosis Cancer
    Casein Kinase inhibitor A51 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities .
    Casein Kinase inhibitor A51
  • HY-P99412
    Lusvertikimab

    OSE-127

    		 Interleukin Related Cancer
    Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
    Lusvertikimab
  • HY-135231
    NL-1
    1 Publications Verification

    		 Mitochondrial Metabolism Autophagy Cancer
    NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 µM and 56.26 µM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway .
    NL-1
  • HY-126566
    Trichostatin C

    		Fungal HDAC Apoptosis Infection Cancer
    Trichostatin C is an inhibitor for histone deacetylase (HDAC), induces apoptosis and arrests cell cycle at G2/M phase, and exhibits anticancer activity against lung cancer and urothelial bladder cancer . Trichostatin C induces differentation of Friend leukemic cells . Trichostatin C exhibits antifungal activity .
    Trichostatin C
  • HY-112885A
    nor-NOHA acetate

    Nω-Hydroxy-nor-L-arginine acetate

    		 Arginase Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    nor-NOHA acetate (Nω-Hydroxy-nor-L-arginine acetate) is a specific and reversible arginase inhibitor, induces apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Anti-leukemic activity, effective in endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA acetate
  • HY-N0732
    Jolkinolide B

    		Apoptosis Cancer
    Jolkinolide B, a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud, is known to induce apoptosis in cancer cells .
    Jolkinolide B
  • HY-147934
    HDAC8-IN-3

    		HDAC Apoptosis Cancer
    HDAC8-IN-3 (compound P19) is a potent HDAC8 inhibitor with IC50 value of 9.3 μM and produces thermal stabilization. HDAC8-IN-3 has cytotoxicity and induces apoptosis in leukemic cell lines .
    HDAC8-IN-3
  • HY-123159
    AKI603

    		Aurora Kinase Cancer
    AKI603 is an inhibitor of Aurora kinase A (AurA), with an IC50 of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells .
    AKI603
  • HY-112885C
    nor-NOHA dihydrochloride
    1 Publications Verification

    Nω-Hydroxy-nor-L-arginine dihydrochloride

    		 Apoptosis Arginase Metabolic Disease Inflammation/Immunology Cancer
    nor-NOHA dihydrochloride is a selective and reversible arginase inhibitor. nor-NOHA dihydrochloride induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA dihydrochloride has anti-leukemic activity. nor-NOHA dihydrochloride can used in study endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA dihydrochloride
  • HY-P3245
    HXR9

    		Apoptosis Cancer
    HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells .
    HXR9
  • HY-P3245A
    HXR9 hydrochloride

    		Apoptosis Cancer
    HXR9 hydrochloride is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 hydrochloride antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 hydrochloride selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells .
    HXR9 hydrochloride
  • HY-112041
    Unesbulin
    3 Publications Verification

    PTC596

    		 Apoptosis Cancer
    Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity .
    Unesbulin
  • HY-N0928
    Mimosine

    Mimosine, a tyrosine analog , can act as an antioxidant by its potent iron-binding activity . Mimosine is a known chelator of Fe(III) . Mimosine induces apoptosis through metal ion chelation, mitochondrial activation and ROS production in human leukemic cells . Anti-cancer, antiinflammation.
    Mimosine
  • HY-153775
    UC-764864

    		E1/E2/E3 Enzyme Cancer
    UC-764864 is a UBE2N inhibitor. UC-764864 inhibits UBE2N enzymatic activity. UC-764864 has cytotoxic effects and inhibition of UBE2N-dependent signaling in leukemic cells. UC-764864 blocks ubiquitination of innate immune- and inflammatory-related substrates in human AML cell lines .
    UC-764864
  • HY-160415
    WD6305

    		PROTACs Apoptosis Cancer
    WD6305 is a potent METTL3-targeted PROTAC degrader. WD6305 selectively reduces the METTL3 and METTL14 complex. WD6305 inhibits m 6A modification and the proliferation of AML cells and promotes apoptosis. WD6305 can be used for the research of leukemic .
    WD6305
  • HY-112885B
    nor-NOHA monoacetate
    1 Publications Verification

    Nω-Hydroxy-nor-L-arginine monoacetate

    		 Arginase Metabolic Disease
    nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA monoacetate
  • HY-101991
    ML291

    		PERK Eukaryotic Initiation Factor (eIF) Apoptosis Cancer
    ML291 is a UPR (unfolded protein response)-inducing sulfonamidebenzamide. ML291 overwhelms the adaptive capacity of the UPR and induces apoptosis in a variety of solid cancer models. ML291 can activate the PERK/eIF2a/CHOP (apoptotic) arm of the UPR and reduce leukemic cell burden .
    ML291
  • HY-155556
    ZG36

    		ClpP Biochemical Assay Reagents Cancer
    ZG36 is a human Caseinolytic protease P (ClpP) agonist. ZG36 non-selectively degrades respiratory chain complexes and reduces mitochondrial DNA, ultimately leading to mitochondrial dysfunction and leukemic cell death. ZG36 also inhibits the development of acute myeloid leukemia in a xenograft mouse model .
    ZG36
  • HY-P3083
    N-Myristoyl-Lys-Arg-Thr-Leu-Arg

    		PKC Inflammation/Immunology
    N-Myristoyl-Lys-Arg-Thr-Leu-Arg is a protein kinase C (PKC) inhibitor with an IC50 value of 75 μM. N-Myristoyl-Lys-Arg-Thr-Leu-Arg inhibits IL-2 receptor induction and IL-2 production in the human leukemic cell line Jurkat .
    N-Myristoyl-Lys-Arg-Thr-Leu-Arg
  • HY-113221
    Isovalerylcarnitine

    		Proteasome Endogenous Metabolite Metabolic Disease
    Isovalerylcarnitine is a product of the catabolism of L-leucine. Isovalerylcarnitine is also a selective and reversible calpain activator that induces apoptosis .
    Isovalerylcarnitine
  • HY-141429
    AS-99 free base

    		Histone Methyltransferase Apoptosis Cancer
    AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
    AS-99 free base
  • HY-141429C
    AS-99

    		Histone Methyltransferase Apoptosis Cancer
    AS-99 is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
    AS-99
  • HY-146230
    VEGFR-2-IN-26

    		VEGFR Cancer
    VEGFR-2-IN-26 (compound 5h) is a highly potent VEGFR-2 inhibitor with an IC50 value of 15.5 nM. VEGFR-2-IN-26 has good antiproliferative activity against the leukemic, non-small lung, CNS, ovarian, renal, prostate and breast cancer cells .
    VEGFR-2-IN-26
  • HY-160415A
    WD6305 TFA

    		PROTACs Apoptosis Cancer
    WD6305 TFA is a potent METTL3-targeted PROTAC degrader. WD6305 TFA selectively reduces the METTL3 and METTL14 complex. WD6305 TFA inhibits m 6A modification and the proliferation of AML cells and promotes apoptosis. WD6305 TFA can be used for the research of leukemic .
    WD6305 TFA
  • HY-141429A
    AS-99 TFA

    		Histone Methyltransferase Apoptosis Cancer
    AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
    AS-99 TFA
  • HY-158019
    Anticancer agent 196

    		DNA/RNA Synthesis Cancer
    Anticancer agent 196 (compound 1) shows cell cytotoxicity with IC50  values of  7.69 µM and  54.2 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 196 can induce DNA damage .
    Anticancer agent 196
  • HY-158020
    Anticancer agent 197

    		DNA/RNA Synthesis Cancer
    Anticancer agent 197 (compound 2b) shows cell cytotoxicity with IC50  values of  10.03 µM and  73.54 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 197 can induce DNA damage .
    Anticancer agent 197
  • HY-115768
    Compound 48/80

    Poly-p-methoxyphenethylmethylamine

    		 Others Neurological Disease Cancer
    Compound 48/80 (Poly-p-methoxyphenethylmethylamine) is widely used in animal and tissue models as a "selective" mast cell activator. Compound 48/80 acts at the mast cell membrane to stimulate trimeric G-proteins and induces degranulation via phospholipase C and D pathways .
    Compound 48/80
  • HY-16209
    Forodesine hydrochloride
    10+ Cited Publications

    BCX-1777 hydrochloride; Immucillin-H hydrochloride

    		 Nucleoside Antimetabolite/Analog Apoptosis Cancer
    Forodesine hydrochloride (BCX-1777 hydrochloride) is a highly potent and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50 values ranging from 0.48 to 1.57 nM for human, mouse, rat, monkey and dog PNP. Forodesine hydrochloride is a potent human lymphocyte proliferation inhibitor. Forodesine hydrochloride could induce apoptosis in leukemic cells by increasing the dGTP levels .
    Forodesine hydrochloride
  • HY-16210
    Forodesine
    10+ Cited Publications

    BCX-1777; Immucillin-H

    		 Nucleoside Antimetabolite/Analog Apoptosis Cancer
    Forodesine (BCX-1777) is a highly potent and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50 values ranging from 0.48 to 1.57 nM for human, mouse, rat, monkey and dog PNP. Forodesine is a potent human lymphocyte proliferation inhibitor. Forodesine could induce apoptosis in leukemic cells by increasing the dGTP levels .
    Forodesine
  • HY-10971A
    Alisertib sodium

    MLN 8237 sodium

    		 Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib sodium
  • HY-123955
    Casein Kinase inhibitor A86

    		Casein Kinase CDK Apoptosis Cancer
    Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities .
    Casein Kinase inhibitor A86
  • HY-10971
    Alisertib
    Maximum Cited Publications
    38 Publications Verification

    MLN 8237

    		 Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib
  • HY-118452
    cis-3,4',5-Trimethoxy-3'-hydroxystilbene

    		Microtubule/Tubulin Apoptosis Cancer
    cis-3,4',5-Trimethoxy-3'-hydroxystilbene is a stilbene. cis-3,4',5-Trimethoxy-3'-hydroxystilbene induces cytochrome c release to the cytoplasm. cis-3,4',5-Trimethoxy-3'-hydroxystilbene-induced apoptosis is associated with mitochondrial release of cytochrome c. cis-3,4',5-Trimethoxy-3'-hydroxystilbene also suppresses tubulin polymerization. cis-3,4',5-Trimethoxy-3'-hydroxystilbene can be used for leukemic research .
    cis-3,4',5-Trimethoxy-3'-hydroxystilbene
  • HY-101287
    MPT0B392

    MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line .
    MPT0B392

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: